The gut and brain peptide cholecystokinin (CCK) exerts a number of central nervous effects. Among them are effects on attention and stimulus processing as revealed by modulations of event-related potentials (ERPs). In the present study the time course of central nervous effects after an intranasal administration of CCK-8 was investigated by means of ERPs. ERPs were recorded in an oddball paradigm 15, 30, 60, 90, 120, and 240 min after administration. Following the double-blind intranasal administration of CCK-8 and placebo, the late positive complex (LPC) of the ERP was significantly increased following CCK-8 compared to placebo. This effect was more pronounced in women than in men. The enhancement of the LPC by intranasal CCK-8 was not restricted to a specific recording time but reached its maximum 120 min after administration in men and women. Moreover, results tentatively indicate that 30 min after administration of CCK-8 the LPC increased only in women but not in men. The early effect of intranasal CCK-8 on LPC in women is unlikely to be caused by changes in plasma CCK-8 levels and suggests a direct nose-brain pathway.

Keywords:
Cholecystokinin, Intranasal administration, Event-related potentials, Nose-brain pathway
This content is only available via PDF.
© 2001 S. Karger AG, Basel
2001
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.